Abstract: The first case of 2019 novel coronavirus (COVID-19) was reported in Wuhan, Hubei Province, China and so far more than 2,53,000 infections and over 10,400 deaths have been reported. This virus could transfer during human-to-human close contacts, with a basic reproductive number as 2.2-2.6. For the outbreak of COVID-19 infection, the necessary requirement for efficient antiviral treatment is a burning issue. Chloroquine, hydroxychloroquine, chloroquine phosphate, cepharanthine, selamectin, mefloquine hydrochloride, niclosamide, losartan, olmesartan, arbidol, moxifloxacin, lopinaviritonavir, interferon, lopinavir/ritonavir, favipiravir, remdesivir,darunavir, intravenous antibody, traditional Chinese medicine, etc. have been used or suggested for the treatment of novel coronavirus.This study is an overview of these drugs to treat COVID-19.
[1]. Franck Touret, Xavier de Lamballerie, Ofchloroquine and COVID-19, Antiviral Research, 2020; 177: 104762.
[2]. Xueting Yao, Fei Ye, Miao Zhang, Cheng Cui, Baoying Huang, Peihua Niu, Xu Liu, Li Zhao, Erdan Dong, Chunli Song,Siyan Zhan, Roujian Lu, Haiyan Li, Wenjie Tan, Dongyang Liu. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Clinical Infectious Diseases, 2020;ciaa237, Published: 09 March 2020
[3]. JianjunGao, ZhenxueTian, Xu Yang. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends. 2020; 14(1):72-73.
[4]. Hua-Hao Fan, Li-Qin Wang, Wen-Li Liu, Xiao-Ping An, Zhen-Dong Liu, Xiao-Qi He, Li-Hua Song, Yi-Gang Tong.Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.Chinese Medical Journal.March 06,2020.
[5]. JiminXu, Pei-Yong Shi, HongminLi, JiaZhou. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.ACS Infect Dis. 2020 Mar 3.[Epub ahead of print]